Use of partial area under the curve metrics to assess bioequivalence of methylphenidate multiphasic modified release formulations.
作者信息
Stier Ethan M, Davit Barbara M, Chandaroy Parthapratim, Chen Mei-Ling, Fourie-Zirkelbach Jeanne, Jackson Andre, Kim Stephanie, Lionberger Robert, Mehta Mehul, Uppoor Ramana S, Wang Yaning, Yu Lawrence, Conner Dale P
机构信息
Division of Bioequivalence, Office of Generic Drugs, Food and Drug Administration, 7520 Standish Place MPNI, Rockville, MF 20855 Maryland, USA.
出版信息
AAPS J. 2012 Dec;14(4):925-6. doi: 10.1208/s12248-012-9397-7. Epub 2012 Sep 14.
Abstract
摘要
相似文献
1
Use of partial area under the curve metrics to assess bioequivalence of methylphenidate multiphasic modified release formulations.使用曲线下部分面积指标评估哌甲酯多相缓释制剂的生物等效性。
AAPS J. 2012 Dec;14(4):925-6. doi: 10.1208/s12248-012-9397-7. Epub 2012 Sep 14.
2
Do regulatory bioequivalence requirements adequately reflect the therapeutic equivalence of modified-release drug products?监管生物等效性要求是否充分反映了缓释药物产品的治疗等效性？
J Pharm Pharm Sci. 2010 May 10;13(1):107-13. doi: 10.18433/j32g6p.
3
Differences in the in vitro and in vivo pharmacokinetic profiles of once-daily modified-release methylphenidate formulations in Canada: examination of current bioequivalence criteria.加拿大每日一次的缓释哌甲酯制剂的体外和体内药代动力学特征的差异：对现行生物等效性标准的考察。
Clin Ther. 2012 May;34(5):1170-81. doi: 10.1016/j.clinthera.2012.02.010. Epub 2012 Apr 17.
4
Lack of bioequivalence between two methylphenidate extended modified release formulations in healthy volunteers.两种哌甲酯缓释改良制剂在健康志愿者中缺乏生物等效性。
Int J Clin Pharmacol Ther. 2009 Dec;47(12):761-9. doi: 10.5414/cpp47761.
5
Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults.两种缓释制剂在健康成年人中口服后哌甲酯的药代动力学。
Clin Pharmacokinet. 2003;42(4):393-401. doi: 10.2165/00003088-200342040-00007.
6
Flawed attention-deficit/hyperactivity disorder medication comparison.有缺陷的注意力缺陷多动障碍药物比较。
Pediatrics. 2004 Oct;114(4):1132; author reply 1132-3. doi: 10.1542/peds.2004-1310.
7
A pharmacokinetic study of two modified-release methylphenidate formulations under different food conditions in healthy volunteers.在健康志愿者中，于不同饮食条件下对两种缓释哌甲酯制剂进行的药代动力学研究。
Int J Clin Pharmacol Ther. 2008 Sep;46(9):466-76. doi: 10.5414/cpp46466.
8
Bioequivalence of a methylphenidate hydrochloride extended-release preparation: comparison of an intact capsule and an opened capsule sprinkled on applesauce.盐酸哌甲酯缓释制剂的生物等效性：完整胶囊与撒于苹果酱上的打开胶囊的比较。
Int J Clin Pharmacol Ther. 2006 Mar;44(3):135-41. doi: 10.5414/cpp44135.
9
Single-dose Pharmacokinetic Properties and Relative Bioavailability of a Novel Methylphenidate Extended-release Chewable Tablet Compared With Immediate-release Methylphenidate Chewable Tablet.新型哌甲酯缓释咀嚼片与速释哌甲酯咀嚼片的单剂量药代动力学特性及相对生物利用度比较
Clin Ther. 2016 May;38(5):1151-7. doi: 10.1016/j.clinthera.2016.02.026. Epub 2016 Mar 24.
10
Relative Bioavailability of Methylphenidate Extended-release Chewable Tablets Chewed Versus Swallowed Whole.盐酸哌甲酯控释咀嚼片咀嚼与整片吞服的相对生物利用度。
Clin Ther. 2018 May;40(5):733-740. doi: 10.1016/j.clinthera.2018.03.016. Epub 2018 Apr 25.
引用本文的文献
1
Double Peaking Phenomena in Pharmacokinetic Disposition Revisited.重新审视药代动力学处置中的双峰现象。
Clin Pharmacokinet. 2025 Aug 13. doi: 10.1007/s40262-025-01559-4.
2
Methylphenidate Multiphasic Release Tablet: Bioequivalence Assessment between Two Formulations Administered under Fasting and Fed Conditions.哌甲酯多相释放片：两种制剂在禁食和进食条件下给药的生物等效性评估。
Pharmaceutics. 2023 Jun 14;15(6):1737. doi: 10.3390/pharmaceutics15061737.
3
An In Silico Approach toward the Appropriate Absorption Rate Metric in Bioequivalence.生物等效性中合适吸收速率指标的计算机模拟方法。
Pharmaceuticals (Basel). 2023 May 10;16(5):725. doi: 10.3390/ph16050725.
4
The Two Main Goals of Bioequivalence Studies.生物等效性研究的两个主要目标。
AAPS J. 2017 Jul;19(4):885-890. doi: 10.1208/s12248-017-0048-x. Epub 2017 Feb 2.
5
Population pharmacokinetics of methylphenidate hydrochloride extended-release multiple-layer beads in pediatric subjects with attention deficit hyperactivity disorder.盐酸哌甲酯缓释多层微丸在患有注意力缺陷多动障碍的儿科受试者中的群体药代动力学。
Drug Des Devel Ther. 2015 May 26;9:2767-75. doi: 10.2147/DDDT.S83234. eCollection 2015.
6
Impact of release mechanism on the pharmacokinetic performance of PAUC metrics for three methylphenidate products with complex absorption.影响释放机制对三种具有复杂吸收的哌醋甲酯产品 PAUC 指标药代动力学性能的影响。
Pharm Res. 2014 Jan;31(1):173-81. doi: 10.1007/s11095-013-1150-0. Epub 2013 Aug 7.
本文引用的文献
1
Using partial area for evaluation of bioavailability and bioequivalence.利用部分面积评估生物利用度和生物等效性。
Pharm Res. 2011 Aug;28(8):1939-47. doi: 10.1007/s11095-011-0421-x. Epub 2011 Apr 13.
2
Challenges and opportunities in establishing scientific and regulatory standards for assuring therapeutic equivalence of modified release products: workshop summary report.建立确保缓控释产品治疗等效性的科学和监管标准的挑战和机遇：研讨会总结报告。
AAPS J. 2010 Sep;12(3):371-7. doi: 10.1208/s12248-010-9201-5. Epub 2010 May 4.
3
A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).实验室学校中患有注意力缺陷/多动障碍儿童使用每日一次缓释哌甲酯制剂的比较（Comacs研究）
Pediatrics. 2004 Mar;113(3 Pt 1):e206-16. doi: 10.1542/peds.113.3.e206.
Zotero 插件